Using heparin and low-dose aspirin in expectant management of early-onset severe preeclampsia

References

• Villar J, Say L, Gülmezoglu AM et al. Eclampsia and pre-eclampsia: a worldwide health problem for 2000 years. In: Pre-eclampsia. Critchley H, MacLean A, Poston L, Walker J (Eds). RCOG Press, London, UK (2003).
   Google Scholar
• Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb. Haemost.79, 1166–1170 (1998).
   PubMed Web of Science ®Google Scholar
• Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood68, 881–885 (1986).
   PubMed Web of Science ®Google Scholar
• Dekker GA, Sibai BM. Etiology and pathophysiology of pre-eclampsia. Current concepts. AJOG Review. Am. J. Obstet. Gynecol.179, 1359–1375 (1998).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med.340, 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N, Montanaro S. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb. Haemost.81, 349–352 (1999).
   PubMed Web of Science ®Google Scholar
• von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with pre-eclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb. Res.100, 363–365 (2000).
   PubMed Web of Science ®Google Scholar
• Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet. Gynecol.97, 753–759 (2001).
   PubMed Web of Science ®Google Scholar
• D’Elia AV, Driul L, Giacomello R, Colaone R, Fabbro D, Di Leonardo C. Frequency of Factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in pre-eclampsia. Gynecol. Obstet. Invest.53, 84–87 (2002).
   PubMed Web of Science ®Google Scholar
• Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe pre-eclampsia. Am. J. Obstet. Gynecol.185, 153–157 (2001).
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet. Gynecol.99(1), 135–144 (2002).
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. Br. Med. J.322, 329–333 (2001).
   PubMedGoogle Scholar
• Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev.1, CD004659 (2004).
   PubMedGoogle Scholar
• Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst. Rev.2, CD000492 (2000).
   Google Scholar
• Hall DR, Odendaal HJ, Steyn DW, Grové D. Expectant management of early onset, severe pre-eclampsia: maternal outcome. Br. J. Obstet. Gynaecol.107, 1252–1257 (2000).
   Google Scholar
• Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grové D. Expectant management of early onset, severe pre-eclampsia: perinatal outcome. Br. J. Obstet. Gynaecol.107, 1258–1264 (2000).
   Google Scholar
• Hall DR, Odendaal HJ, Steyn DW. Expectant management severe pre-eclampsia in the mid-trimester. Eur. J. Obstet. Gynecol. Reprod. Biol.96, 168–172 (2001).
   PubMed Web of Science ®Google Scholar
• The Grit Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. Br. J. Obstet. Gynaecol.110, 27–32 (2003).
   Google Scholar
• Oettle C, Roux A, Hall D. Expectant management of early onset severe pre-eclampsia at a secondary hospital. Proceedings of: The 22nd Conference on Priorities in Perinatal Care. Free State, South Africa, 11–14 March 2003.
   Google Scholar
• Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet369, 1791–1798 (2007).
   PubMed Web of Science ®Google Scholar
• Chu HN, Zhou CY. Severe preeclampsia cured by heparin in a patient with twin–twin transfusion syndrome. Chin. Med. J. (Engl.)120(3), 263–264 (2007).
   PubMedGoogle Scholar
• Fairley KF, Adey FD, Ross IC, Kincaid-Smith P. Heparin treatment in severe preeclampsia and glomerulonephritis in pregnancy. Perspect. Nephrol. Hypertens.5, 103–112 (1976).
   PubMedGoogle Scholar
• Whitworth JA, Fairley KF. Heparin in the treatment of preeclamptic toxemia. Perspect. Nephrol. Hypertens.1(Pt 2), 1027–1029 (1973).
   PubMedGoogle Scholar
• Howie PW, Prentice CR, Forbes CD. Failure of heparin therapy to affect the clinical course of severe pre-eclampsia. Br. J. Obstet. Gynaecol.82(9), 711–777 (1975).
   PubMedGoogle Scholar
• Kobayashi T, Terao T, Ikenoue T et al.; BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin. Thromb. Hemost.29(6), 645–652 (2003).
   PubMed Web of Science ®Google Scholar
• Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von Dadelszen PL. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens. Pregnancy28(3), 312 (2009).
   PubMed Web of Science ®Google Scholar